A single centre experience of switching from intravenous to subcutaneous immunoglobin as treatment for Juvenile dermatomyositis (JDM)

Authors
Category Primary study
Conference31st European Paediatric Rheumatology Congress
Year 2024
This article has no abstract
Epistemonikos ID: fbd64949f95c9cf0b04b9a5f6a4e47c39b5f75e0
First added on: Jan 10, 2026